Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11110764 | 0.82 | LMNA (0.43) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11111501 | 0.79 | KMT2A (0.41) | CA12CA1CA2CA9LMNA | |
| SCHEMBL27442483 | 0.75 | TAAR1 (0.43) | CA12CA1CA2CA9LMNA | |
| SCHEMBL7803810 | 0.72 | KMT2A (0.51) | CA12CA1CA2CA9LMNA | |
| SCHEMBL15024488 | 0.71 | NFE2L2 (0.43) | CA12CA1CA2CA9LMNA | |
| SCHEMBL1979557 | 0.71 | — | — | |
| SCHEMBL6236180 | 0.71 | — | — | |
| SCHEMBL4262422 | 0.71 | — | — | |
| SCHEMBL6131634 | 0.71 | — | — | |
| SCHEMBL17635577 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0830357-A4 | RADIOSENSITIZING DIAMINES AND THEIR PHARMACEUTICAL PREPARATIONS | UNIV FLORIDA STATE (US) | 2000-01-19 | — | — | EP | claimed |
| EP-0830357-A1 | RADIOSENSITIZING DIAMINES AND THEIR PHARMACEUTICAL PREPARATIONS | FLORIDA STATE UNIVERSITY (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996030365-A1 | RADIOSENSITIZING DIAMINES AND THEIR PHARMACEUTICAL PREPARATIONS | FLORIDA STATE UNIVERSITY (US) | 1996-10-03 | — | — | WO | claimed |
| US-7608725-B2 | Processes for nitration of N-substituted imidazoles | THE RICHARD STOCKTON COLLEGE OF NEW JERSEY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080045722-A1 | PROCESSES FOR NITRATION OF N-SUBSTITUTED IMIDAZOLES | THE RICHARD STOCKTON COLLEGE OF NEW JERSEY | 2008-02-21 | — | — | US | disclosed |
| WO-2007134187-A2 | PROCESSES FOR NITRATION OF N-SUBSTITUTED IMIDAZOLES | THE RICHARD STOCKTON COLLEGE OF NEW JERSEY (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045722-A1 | PROCESSES FOR NITRATION OF N-SUBSTITUTED IMIDAZOLES | NOS2, NOS1, NOS3 | CA12 3585/4885CA1 3465/4885CA2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.